Sr. Manager, Market Research and Insights
Viridian Therapeutics, Inc.Highlight
Summary
About the Role
About You
- Bachelor's degree (advanced degree preferred, MBA or related field).
- 5+ years of progressive experience in primary market research, market insight, and analytics in the biotech/pharmaceutical industry.
- Strong hands-on experience leading end-to-end primary research projects.
- Deep expertise in primary market research methodologies (qualitative and quantitative).
- Strong analytical skills, including experience with visualization tools (Tableau).
- Solid understanding of biopharma commercialization and launch planning.
- Experience supporting product launches; rare disease or specialty market experience.
- Demonstrated ability to synthesize disparate data sources into clear, strategic insights.
- Strong written and verbal communication skills.
- Proficient with Microsoft Office suite.
Benefits
- Competitive pay and stock options for all employees.
- Competitive medical, dental, and vision insurance.
- 100% Paid Parental Leave.
- Short- and long-term disability coverage.
- Life, Travel and AD&D insurance.
- 401(k) Company Match with immediate company vest.
- Employee Stock Purchase plan.
- Generous vacation plan and paid company holiday shutdowns.
- Various fertility, mental, financial, and proactive physical health programs.
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.